Purpose: The clinical diagnosis of pulmonary involvement in individuals with systemic AL amyloidosis remains challenging. [18F]florbetapir imaging has previously identified AL amyloid deposits in the heart and extra-cardiac organs. The aim of this study is to determine quantitative [18F]florbetapir pulmonary kinetics to identify pulmonary involvement in individuals with systemic AL amyloidosis.
Methods: We prospectively enrolled 58 subjects with biopsy-proven AL amyloidosis and 9 control subjects (5 without amyloidosis and 4 with ATTR cardiac amyloidosis). Pulmonary [18F]florbetapir uptake was evaluated visually and quantified as distribution volume of specific binding (Vs) derived from compartmental analysis and simpler semiquantitative metrics of maximum standardized uptake values (SUVmax), retention index (RI), and target-to-blood ratio (TBR).
Results: On visual analysis, pulmonary tracer uptake was absent in most AL subjects (40/58, 69%); 12% (7/58) of AL subjects demonstrated intense bilateral homogeneous tracer uptake. In this group, compared to the control group, Vs (median Vs 30-fold higher, 9.79 vs. 0.26, p < 0.001), TBR (median TBR 12.0 vs. 1.71, p < 0.001), and RI (median RI 0.310 vs. 0.033, p < 0.001) were substantially higher. Notably, the AL group without visually apparent pulmonary [18F]florbetapir uptake also demonstrated a > 3-fold higher Vs compared to the control group (median 0.99 vs. 0.26, p < 0.001). Vs was independently related to left ventricular SUVmax, a marker of cardiac AL deposition, but not to ejection fraction, a marker of cardiac dysfunction. Also, intense [18F]florbetapir lung uptake was not related to [11C]acetate lung uptake, suggesting that intense [18F]florbetapir lung uptake represents AL amyloidosis rather than heart failure.
Conclusions: [18F]florbetapir PET/CT offers the potential to noninvasively identify pulmonary AL amyloidosis, and its clinical relevance warrants further study.
Keywords: AL; Lung; PET/CT; Quantitative; Systemic light chain amyloidosis; [18F]florbetapir.
Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body 18F-Florbetapir PET/CT.J Nucl Med. 2019 Sep;60(9):1234-1239. doi: 10.2967/jnumed.118.221770. Epub 2019 Apr 6. J Nucl Med. 2019. PMID: 30954943 Free PMC article.
Extracardiac 18F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds.Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1129-1138. doi: 10.1007/s00259-018-3995-2. Epub 2018 Apr 12. Eur J Nucl Med Mol Imaging. 2018. PMID: 29651545 Free PMC article.
Imaging cardiac amyloidosis: a pilot study using ¹⁸F-florbetapir positron emission tomography.Eur J Nucl Med Mol Imaging. 2014 Sep;41(9):1652-62. doi: 10.1007/s00259-014-2787-6. Epub 2014 May 20. Eur J Nucl Med Mol Imaging. 2014. PMID: 24841414 Clinical Trial.
A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement.Amyloid. 2018 Dec;25(4):247-252. doi: 10.1080/13506129.2018.1552852. Epub 2019 Jan 19. Amyloid. 2018. PMID: 30661419
18F-FDG PET/CT in patients with amyloid light-chain amyloidosis: case-series and literature review.Amyloid. 2012 Jun;19(2):94-8. doi: 10.3109/13506129.2012.682833. Epub 2012 May 16. Amyloid. 2012. PMID: 22587492 Review.